CompletedPhase 2NCT02290613

Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Heidelberg University
Principal Investigator
Ekkehard Grünig, MD
Thoraxclinic at the University of Heidelberg
Intervention
Ambrisentan(drug)
Enrollment
38 enrolled
Eligibility
18 years · All sexes
Timeline
20142017

Study locations (1)

Collaborators

GlaxoSmithKline

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02290613 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis

← Back to all trials